Granules India receives EIR from USFDA for Gagillapur facility

16 Aug 2017 Evaluate

Granules India’s Gagillapur facility located at Hyderabad, Telangana, India has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). This facility was inspected by USFDA in October 2016 and there were no observations during the inspection. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

564.95 -6.25 (-1.09%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×